Olaparib for BRCA-mutated advanced ovarian cancer

被引：2
|
作者：
de Lartigue, Jane
机构：
来源：
JOURNAL OF COMMUNITY AND SUPPORTIVE ONCOLOGY | 2015年 / 13卷 / 06期
关键词：
D O I：
10.12788/jcso.0138
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：206 / 208
页数：3
相关论文
共 50 条
  • [1] Olaparib for the treatment of BRCA-mutated advanced ovarian cancer
    Munroe, Marklie
    Kolesar, Jill
    [J]. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2016, 73 (14) : 1037 - 1041
  • [2] Overview: FDA Approval of Olaparib Maintenance for BRCA-Mutated Ovarian Cancer
    Saleh, Naveed
    Copur, Mehmet Sitki
    [J]. ONCOLOGY-NEW YORK, 2019, 33 (07): : 293 - 294
  • [3] Adjuvant Olaparib in BRCA-Mutated Breast Cancer
    Hoshi, Aoi
    Bando, Hiroko
    Sekine, Ikuo
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (15): : 1439 - 1440
  • [4] Olaparib for Metastatic Germline BRCA-Mutated Breast Cancer
    Narod, Steven
    Booth, Christopher M.
    Foulkes, William D.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (18): : 1792 - 1792
  • [5] Adjuvant Olaparib in BRCA-Mutated Breast Cancer REPLY
    Tutt, Andrew N. J.
    Garber, Judy E.
    Geyer, Charles E., Jr.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (15): : 1440 - 1440
  • [6] Progress in BRCA-Mutated Ovarian Cancer
    Spriggs, David R.
    Longo, Dan L.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (26): : 2567 - 2568
  • [7] Spotlight on olaparib in the treatment of BRCA-mutated ovarian cancer: design, development and place in therapy
    Lorusso, Domenica
    Tripodi, Elisa
    Maltese, Giuseppa
    Lepori, Stefano
    Sabatucci, Ilaria
    Bogani, Giorgio
    Raspagliesi, Francesco
    [J]. DRUG DESIGN DEVELOPMENT AND THERAPY, 2018, 12 : 1501 - 1509
  • [8] Olaparib as first line in BRCA-mutated advanced ovarian carcinoma: Is it cost-effective in Spain
    Moya-Alarcon, Carlota
    Gonzalez-Dominguez, Almudena
    Ivanova-Markova, Yoana
    Gimeno-Ballester, Vicente
    Barretina-Ginesta, Maria-Pilar
    Alejandro Perez-Fidalgo, Jose
    Redondo, Andres
    [J]. GYNECOLOGIC ONCOLOGY, 2022, 164 (02) : 406 - 414
  • [9] Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer
    Golan, Talia
    Hammel, Pascal
    Reni, Michele
    Van Cutsem, Eric
    Macarulla, Teresa
    Hall, Michael J.
    Park, Joon-Oh
    Hochhauser, Daniel
    Arnold, Dirk
    Oh, Do-Youn
    Reinacher-Schick, Anke
    Tortora, Giampaolo
    Alguel, Hana
    O'Reilly, Eileen M.
    McGuinness, David
    Cui, Karen Y.
    Schlienger, Katia
    Locker, Gershon Y.
    Kindler, Hedy L.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (04): : 317 - 327
  • [10] Comparison of survival outcomes between olaparib and niraparib maintenance therapy in BRCA-mutated, newly diagnosed advanced ovarian cancer
    Kim, Ji Hyun
    Kim, Se Ik
    Park, Eun Young
    Kim, Eun Taeg
    Kim, Hyesu
    Kim, Sangeon
    Park, Sang-Yoon
    Lim, Myong Cheol
    [J]. GYNECOLOGIC ONCOLOGY, 2024, 181 : 33 - 39
12345